KR850004395A - 류머티스 치료용 약제의 제조방법 - Google Patents
류머티스 치료용 약제의 제조방법 Download PDFInfo
- Publication number
- KR850004395A KR850004395A KR1019840008219A KR840008219A KR850004395A KR 850004395 A KR850004395 A KR 850004395A KR 1019840008219 A KR1019840008219 A KR 1019840008219A KR 840008219 A KR840008219 A KR 840008219A KR 850004395 A KR850004395 A KR 850004395A
- Authority
- KR
- South Korea
- Prior art keywords
- glycero
- acid
- diacyl
- weight percent
- radicals
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 7
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 6
- 150000003904 phospholipids Chemical class 0.000 claims 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 5
- 239000003960 organic solvent Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 4
- 239000005642 Oleic acid Substances 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 3
- 235000021314 Palmitic acid Nutrition 0.000 claims 3
- 235000021355 Stearic acid Nutrition 0.000 claims 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 3
- 239000001110 calcium chloride Substances 0.000 claims 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims 3
- 235000020650 eye health related herbal supplements Nutrition 0.000 claims 3
- 235000020778 linoleic acid Nutrition 0.000 claims 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 3
- 229960004488 linolenic acid Drugs 0.000 claims 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 3
- 239000008117 stearic acid Substances 0.000 claims 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Natural products CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000003063 flame retardant Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical class OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (15)
- 하기 일반식(I)의 옥시캄 유도체 및 특정 1,2-디아실-글리세로-3-포스포콜린 (여기에서 아실라디칼의 75내지 86중량%가 탄소수 16,18 및/또는 20의 불포화 지방산 라디칼 또는 이의 혼합기이다)을 통상의 보조제 및 충진제와 혼합시킨 후 캡슐에 충진시키거나 타정시켜, 인지질 및 비스테로이드성 소염제를 1:1내지 20:1의 몰비로 함유하는, 류머티스 치료용 약제학적 제제를 제조하는 방법.상기식에서, R1은 피리딘 또는 5-메틸-3-이속사졸과 같은 헤테로사이클릭환이고, R2및 R3는 함께벤젠 또는 티오펜 환과 같은 축합된 방향족 환을 형성한다.
- 하기 일반식(I)의 옥시캄 유도체를 특정 1,2-디아실-글리세로-3-포스포콜린(여기에서 아실라디칼의 75내지 86중량%가 탄소수 16,18 및/또는 20의 불포화 지방산 라디칼 또는 이의 혼합기 이다)의 액체 물질중에서 통상적 보조제 존재하에 교반시킨 후, 액체 형태로 경질 젤라틴 캡슐내에 충진시켜, 인지질 및 비스테로이드성 소염제를 1:1내지 20:1의 몰비로 함유하는, 류머티스치료용 약제학적 제제를 제조하는 방법.상기식에서, R1은 피리딘 또는 5-메틸-3-이속사졸과 같은 헤테로사이클릭 환이고, R2및 R3는 함께 벤젠 또는 티오펜환과 같은 축합된 방향족 환을 형성한다.
- 하기 일반식(I)의 옥시캄 유도체 및 즉정 1,2-디아실-글리세로-3-포스포콜린(여기에서 아실 라디칼의 75내지 86중량%가 탄소수 16,18 및/또는 20의 불포화 지방산 라디칼 또는 이의 혼합기이다)을 물 또는 유기용맹 중에서 함께 용해시키거나 유화시키고, 물 또는 알콜중에 용해되거나 슬러리화된 염화 칼슘을 가한 후, 용매를 제거하고, 수득된 생성물을 건조시키고 임의로 분쇄시킨 후, 약제학적 제제로 제형화시켜, 인지질 및 비스테로이드성 소염제를 1:1내지 20:1의 몰비로 함유하는, 류머티스 치료용 약제학적 제제를 제조하는 방법.상기식에서, R1은 피리딘 또는 5-메틸-3-이속사졸과 같은 헤테로사이클릭 환이고, R2및 R3는 함께 벤젠 또는 티오펜환과 같은 축합된 방향족 환을 형성한다.
- 하기 일반식(I)의 옥시캄 유도체를 목적한 입자 크기로 분쇄시키고, 분말상의 특정 1,2-디아실-글리세로-3-포스포콜린-염화 칼슘 혼합물(여기에서 아실 라디칼의 75내지 86중량%가 탄소수 16,18 및/또는 20의 불포화 지방산 라디칼 또는 이의 혼합기이다)과 혼합시킨 후, 정제 및 캡슐 같은 통상의 약제형태로 제형화시켜, 인지질 및 비스테로이드성 소염제를 1:1내지 20:1의 몰비로 함유하는, 류머티스 치료용 약제학적 제제를 제조하는 방법.상기식에서 R1은 피리딘 또는 5-메틸-3-이속사졸과 같은 헤테로사이클릭 환이고, R2및 R3는 함께 벤젠 또는 티오펜환과 같은 축합된 방향족 환을 형성한다.
- 유기용매 또는 물중의 하기 일반식(I)의 옥시캄 유도체의 용액 또는 분산액을, 유기 용매 또는 물중의 특정 1,2-디아실-글리세로-3-포스포콜린(여기에서 아실 라디칼의 75내지 86중량%가 탄소수 16,18 및/또는 20의 불포화 지방산 라디칼 또는 이의 혼합기이다)의 용액 또는 유제 및 유기용매 또는 물중의 염화 칼슘 용액 및 임의로 통상의 생약 보조물질과 함께 혼합시키고 분무 건조시킨 후, 수득된 분무건조 물질을 임의로 생약 보조 물질의 부가하에 타정시키거나 캡슐에 충진시켜, 인지질 및 비스테로이드성 소연제를 1:1내지 20:1의 몰비로 함유하는, 류머티스 치료용 약제학적 제제를 제조하는 방법.상기식에서 R1은 피리딘 또는 5-메틸-3-이속사졸과 같은 헤테로사이클릭환이고, R2및 R3는 함께 벤젠 또는 티오펜환과 같은 축합된 방향족 환을 형성한다.
- 유기 용매 또는 물중의 특정 1,2-디아실-글리세로-3-포스포콜린(여기에서 아실 라디칼의 75내지 86중량%가 탄소수 16,18 및/또는 20의 불포화 지방산 라디칼 또는 이의 혼합기이다)의 용액 또는 유제를 유기 용매 또는 물중의 염화칼슘 용액과 혼합시키고, 미리 목적한 입자 크기로 분쇄시킨 하기 일반식(I)의 옥시캄 유도체에 유동상 내에서 가한 후, 수득된 분말상의 자유유동성 생성물에 생약 보조물질을 부가하여 타정시키거나 캡슐에 충진시켜, 인지질 및 비스테로이드성 소염제를 1:1내지 20:1의 몰비로 함유하는, 류머티스 치료용 약제학적 제제를 제조하는 방법.상기식에서 R1은 피리딘 또는 5-메틸-3-이속사졸과 같은 헤테로사이클릭 환이고, R2및 R3는 함께 벤젠 또는 티오펜환과 같은 축합된 방향족 환을 형성한다.
- 제1내지 6항중 어느 하나에 있어서, 피록시캄을 옥시캄 유도체로서 함유하는 방법.
- 제1내지 6항중 어느 하나에 있어서, 이속시캄을 옥시캄 유도체로서 함유하는 방법.
- 제1 내지 6항중 어느 하나에 있어서, 테녹시캄을 옥시캄 유도체로서 함유하는 방법.
- 제1내지 9항중 어느 하나에 있어서, 특정 1,2-디아실글리세로-3-포스포콜린의 불포화 지방산 리디칼이 리놀산, 올레산, 및/또는 아라키돈산 라디칼인 방법.
- 제10항에 있어서, 아실 라디칼이, 10내지 20중량%의 팔미트산, 3내지 5중량%의 스테아르산, 8내지 12중량%의 올레산, 62내지 69.5중량%의 리놀산 및 4내지 7중량%의 리놀렌산의 자방산 라디칼의 혼합기이고, 여기서 아실 라디칼 함량이 총 100%가 되도록 선택되고 불포화 아실 라디칼의 비율은 아실라디칼 총량에 대하여 75내지 86중량%인 방법.
- 제10항에 있어서, 지방산 라디칼의 혼합기로서, 1-아실 라디칼이, 22내지 26중량%의 팔미트산, 6내지 9중량%의 스테아르산, 8내지 12중량%의 올레산, 50내지 54중량%의 리놀산 및 4내지 6중량%의 리놀렌산을 함유하고, 2-아실 라디칼이, 1내지 2중량%의 팔미트산, 0내지 1중량%의 스테아르산, 8내지 22중량%의 올레산, 75내지 85중량%의 리놀산 및 5내지 8중량%의 리놀렌산을 함유하며, 여기에서 1-및 2-위치의 아실 라디칼 함량은 각기 총 100중량%이고 불포화 아실 라디칼의 비율은 75내지 86중량%인 방법.
- 제10항에 있어서, 특정 1,2-디아실-글리세로-3-포스포콜린 이외에, 1,2-디아실-글리세로-3-포스페이트, 예를 들어 1,2-디아실-글리세로-3-포스포에탄올아민, 1,2-디아실-글리세로-3-포스포이노시톨, 1,2-디아실-글리세로-3-포스포세린 및 1,2-디아실-글리세로-3-포스포 글리세롤중 하나 이상을 20%이하로 함유하는 방법.
- 제13항에 있어서, 단위 용량당 10내지 20mg의 피록시캄 및 50내지 250mg의 특정 1,2-디아실-글리세로-3-포스포콜린을 함유하는 방법.
- 제1내지 14항중 어느 하나에 있어서, 단위 용량당 5내지 20mg의 옥시캄 유도체 및 10내지 500mg의 특정 1,2디아실-글리세로-3-포스포콜린 이외에, 통상의 보조제 및 충진제를 함유하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3346526A DE3346526C2 (de) | 1983-12-22 | 1983-12-22 | Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen |
| DEP3346526.6 | 1983-12-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR850004395A true KR850004395A (ko) | 1985-07-15 |
| KR920003602B1 KR920003602B1 (ko) | 1992-05-04 |
Family
ID=6217768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019840008219A KR920003602B1 (ko) | 1983-12-22 | 1984-12-21 | 류머티스 치료용 약제의 제조방법 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US4687766A (ko) |
| EP (1) | EP0147735B1 (ko) |
| JP (1) | JPS60169420A (ko) |
| KR (1) | KR920003602B1 (ko) |
| AT (1) | ATE40793T1 (ko) |
| AU (1) | AU566974B2 (ko) |
| CA (1) | CA1234049A (ko) |
| DD (1) | DD233076A5 (ko) |
| DE (2) | DE3346526C2 (ko) |
| DK (1) | DK619484A (ko) |
| EG (1) | EG17137A (ko) |
| ES (1) | ES8707111A1 (ko) |
| FI (1) | FI83287C (ko) |
| GR (1) | GR82545B (ko) |
| HU (1) | HU193729B (ko) |
| IL (1) | IL73849A (ko) |
| IN (1) | IN162327B (ko) |
| MX (1) | MX159874A (ko) |
| NO (1) | NO166569C (ko) |
| NZ (1) | NZ210648A (ko) |
| OA (1) | OA07907A (ko) |
| PH (1) | PH21823A (ko) |
| PT (1) | PT79649B (ko) |
| ZA (1) | ZA849976B (ko) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5154930A (en) * | 1987-03-05 | 1992-10-13 | The Liposome Company, Inc. | Pharmacological agent-lipid solution preparation |
| US5376381A (en) * | 1988-02-25 | 1994-12-27 | The Liposome Company, Inc. | Integrity protected gelatin |
| GB9212450D0 (en) * | 1992-06-11 | 1992-07-22 | Indena Spa | New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them |
| GB9325445D0 (en) | 1993-12-13 | 1994-02-16 | Cortecs Ltd | Pharmaceutical formulations |
| US5763422A (en) * | 1995-01-27 | 1998-06-09 | Board Of Regents, The University Of Texas System | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| US5955451A (en) * | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| AUPN766496A0 (en) * | 1996-01-22 | 1996-02-15 | University Of New England, The | Method and composition for the potentiation of anti-inflammatory drugs |
| PL371626A1 (en) * | 2002-01-21 | 2005-06-27 | Vasogen Ireland Limited | Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| BR0215680A (pt) * | 2002-04-26 | 2005-02-01 | Rudolf Perl | Composição farmacêutica oral estável |
| KR20060037369A (ko) * | 2003-07-21 | 2006-05-03 | 바소겐 아일랜드 리미티드 | 급성 염증 상태의 치료를 위한 포스페이트 글리세롤 기를함유하는 리포솜 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3787324A (en) * | 1971-03-01 | 1974-01-22 | Warner Lambert Co | 4-hydroxy-3-(3-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,dioxides and process for their production |
| FR2343481A1 (fr) * | 1976-03-11 | 1977-10-07 | Gerlich Norbert | Composition destinee a empecher les lesions des membranes biologiques et a regenerer ces membranes une fois qu'elles ont ete endommagees |
| AU518216B2 (en) * | 1977-09-06 | 1981-09-17 | Hafslund Nycomed Pharma Aktiengesellschaft | Thienothiazine derivatives |
| JPS54117034A (en) * | 1978-02-28 | 1979-09-11 | Nippon Shoji Kk | Treating agent for consciousness and perception motion disorder |
| DE2856333C2 (de) * | 1978-12-27 | 1983-09-22 | A. Nattermann & Cie GmbH, 5000 Köln | Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung |
| DE2856339C2 (de) * | 1978-12-27 | 1985-12-05 | Fortuna-Werke Maschinenfabrik Gmbh, 7000 Stuttgart | Vorrichtung zum kontinuierlichen, automatischen Zustellen von Setzstockbacken zur Halterung eines Werkstückes auf einer Rundschleifmaschine |
| DE2914788A1 (de) * | 1979-04-11 | 1980-10-16 | Nattermann A & Cie | Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung |
| DE3047011A1 (de) * | 1980-12-13 | 1982-07-22 | A. Nattermann & Cie GmbH, 5000 Köln | Verfahren zur abtrennung von oel und/oder phosphatidylethanolamin aus diese enthaltenden alkoholloeslichen phosphatidylcholin-produkten |
| DE3047048A1 (de) * | 1980-12-13 | 1982-07-29 | A. Nattermann & Cie GmbH, 5000 Köln | Verfahren zur abtrennung von oel und/oder phosphatidylethanolamin aus diese enthaltenden alkoholloeslichen phosphatidylcholin-produkten |
| DE3047012A1 (de) * | 1980-12-13 | 1982-07-22 | A. Nattermann & Cie GmbH, 5000 Köln | Verfahren zur abtrennung von acylierten phospholipiden aus diese enthaltenden phosphatidylcholin-produkten |
| US4434163A (en) * | 1981-06-01 | 1984-02-28 | Pfizer Inc. | Water-soluble benzothiazine dioxide salts |
| US4434164A (en) * | 1981-06-01 | 1984-02-28 | Pfizer Inc. | Crystalline benzothiazine dioxide salts |
| DE3217315C2 (de) * | 1982-05-08 | 1986-05-22 | Gödecke AG, 1000 Berlin | Arzneimittelzubereitungen mit einem Gehalt an Oxicam-Derivaten |
-
1983
- 1983-12-22 DE DE3346526A patent/DE3346526C2/de not_active Expired
-
1984
- 1984-12-06 NO NO844889A patent/NO166569C/no unknown
- 1984-12-10 PT PT79649A patent/PT79649B/pt not_active IP Right Cessation
- 1984-12-12 CA CA000469960A patent/CA1234049A/en not_active Expired
- 1984-12-13 EP EP84115358A patent/EP0147735B1/de not_active Expired
- 1984-12-13 AT AT84115358T patent/ATE40793T1/de not_active IP Right Cessation
- 1984-12-13 DE DE8484115358T patent/DE3476734D1/de not_active Expired
- 1984-12-14 AU AU36685/84A patent/AU566974B2/en not_active Ceased
- 1984-12-14 IN IN941/DEL/84A patent/IN162327B/en unknown
- 1984-12-18 IL IL73849A patent/IL73849A/xx unknown
- 1984-12-19 FI FI845019A patent/FI83287C/fi not_active IP Right Cessation
- 1984-12-20 GR GR82545A patent/GR82545B/el unknown
- 1984-12-20 DD DD84271295A patent/DD233076A5/de not_active IP Right Cessation
- 1984-12-20 NZ NZ210648A patent/NZ210648A/en unknown
- 1984-12-20 PH PH31618A patent/PH21823A/en unknown
- 1984-12-21 US US06/685,152 patent/US4687766A/en not_active Expired - Lifetime
- 1984-12-21 OA OA58484A patent/OA07907A/xx unknown
- 1984-12-21 MX MX8252A patent/MX159874A/es unknown
- 1984-12-21 ZA ZA849976A patent/ZA849976B/xx unknown
- 1984-12-21 HU HU844806A patent/HU193729B/hu unknown
- 1984-12-21 ES ES538982A patent/ES8707111A1/es not_active Expired
- 1984-12-21 KR KR1019840008219A patent/KR920003602B1/ko not_active IP Right Cessation
- 1984-12-21 DK DK619484A patent/DK619484A/da not_active Application Discontinuation
- 1984-12-22 JP JP59269684A patent/JPS60169420A/ja active Granted
- 1984-12-22 EG EG796/84A patent/EG17137A/xx active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU691250B2 (en) | Lipophilic carrier preparations | |
| CA1092025A (en) | Pharmaceutical preparation adapted for oral administration | |
| JPS6030652B2 (ja) | 静脈注射用脂肪乳剤 | |
| TW416849B (en) | New pharmaceutical composition based on taxoids | |
| GB2039738A (en) | Inflammation - preventing pharmaceutical composition | |
| JPS6295134A (ja) | リポソ−ムの製造法 | |
| KR850004395A (ko) | 류머티스 치료용 약제의 제조방법 | |
| EP0023349A2 (en) | Ubidecarenone composition enhancing the absorption | |
| US4842865A (en) | Use of glycofurol for the liquidization of pharmaceutical preparations to be filled into soft gelatine capsules | |
| JPS58206597A (ja) | 水性燐脂質溶液 | |
| EP0470251B1 (en) | Liquid prostaglandin composition | |
| US3450821A (en) | Stable compositions containing eicosatetrayn - (5,8,11,14) - oic-(1) acid and derivatives thereof | |
| JPS6241209B2 (ko) | ||
| JPS59122423A (ja) | 制癌剤含有脂肪乳剤 | |
| JPH0139406B2 (ko) | ||
| JPS6145637B2 (ko) | ||
| US4150125A (en) | Triglyceride ester of phosphonoacetic acid having antiviral activity | |
| JPS6034907A (ja) | 固体単位投与形を形成するためのビタミンまたはミネラル組成物 | |
| US3849558A (en) | Pharmaceutical compositions having controlled gastro-intestinal absorption | |
| CA1113926A (en) | Pharmaceutical preparation adapted for oral administration | |
| JPS5731614A (en) | Lipid improver | |
| EP0431659B1 (en) | Pharmaceutical compositions of tebufelone | |
| US3962436A (en) | Pharmaceutical compositions having controlled rate of gastro-intestinal absorption | |
| US3639597A (en) | Pharmaceutical compositions containing cholanic acid conjugates | |
| JPH10330250A (ja) | メナテトレノン油性製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19841221 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19911130 Patent event code: PE09021S01D |
|
| G160 | Decision to publish patent application | ||
| PG1605 | Publication of application before grant of patent |
Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19920403 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19920722 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19920930 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19920930 End annual number: 3 Start annual number: 1 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |